Bristol Myers Squibb (BMS) is leveraging an innovative algorithm developed by Viz.ai to detect potential candidates for their heart disease drug. The Viz HCM algorithm recently gained approval from the Food and Drug Administration (FDA) and has the ability to examine electrocardiograms and identify cases of hypertrophic cardiomyopathy (HCM) that may require further evaluation.
By collaborating with Viz.ai, BMS aims to expand the market for their drug, Camzyos, which is specifically designed to treat HCM. As part of this partnership, BMS provided financial support and scientific input to aid in the development of the algorithm.
The motivation behind BMS’s efforts lies in their objective to help more individuals affected by HCM, while also increasing the sales of their drug. Cardiologist Matthew Martinez, who leads Viz.ai’s HCM medical advisory board, expressed that BMS is keen on identifying additional patients for their drug, not solely due to philanthropic reasons, but also to make a positive impact on more lives.
With the implementation of the Viz HCM algorithm, BMS can identify potential candidates early on, ensuring that individuals receive timely and appropriate treatment. This algorithm serves as a valuable tool for healthcare professionals in pinpointing suspected cases of HCM during routine care, contributing to enhanced patient care and potentially saving lives.
Q: What is hypertrophic cardiomyopathy (HCM)?
A: Hypertrophic cardiomyopathy is a heart condition characterized by the thickening of the heart muscle, which can lead to difficulties in breathing and impaired heart function.
Q: What is the purpose of the Viz HCM algorithm?
A: The Viz HCM algorithm is designed to analyze electrocardiograms and flag suspected cases of hypertrophic cardiomyopathy for further evaluation, aiding in the early detection of the condition.
Q: What is the role of Bristol Myers Squibb in this collaboration?
A: Bristol Myers Squibb provided funding and scientific input to support the development of the Viz HCM algorithm in order to identify more patients who could benefit from their heart disease drug.